Drug Profile


Alternative Names: Amlodipine/hydrochlorothiazide/azilsartan; Azilsartan/amlodipine/hydrochlorothiazide; Azilsartan/hydrochlorothiazide/amlodipine; Hydrochlorothiazide/amlodipine/azilsartan; Hydrochlorothiazide/azilsartan/amlodipine; TAK-536/AML/HCTZ; TAK-536TCH

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Dihydropyridines; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Essential hypertension

Most Recent Events

  • 04 Jul 2017 Chemical structure information added
  • 10 May 2017 Discontinued - Preregistration for Essential hypertension in Japan (PO) based on the outcomes of market research (Takeda FY2016 Q4 results, May 2017)
  • 01 Jun 2016 Takeda completes a phase III trial in Essential hypertension in Japan (NCT02277691; JapicCTI-142689)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top